Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

<i>APOE</i> Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.

Journal of Korean medical science·2026
Same author

Nano formulation of Sophora japonica extract stimulates osteogenic activity in osteoblasts.

Journal of food science and technology·2026
Same author

Mixing-sequence-governed dispersion and processability of electrode slurries with carboxymethyl cellulose and cellulose nanofibrils.

Carbohydrate polymers·2026
Same author

A clinically feasible framework to estimate tau pathology and clinical-biological discordance in the Alzheimer's disease spectrum.

Alzheimer's research & therapy·2026
Same author

Prediction of cognitive impairment through speech data analysis: A comparative evaluation of deep learning models.

PloS one·2026
Same author

Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.

BMC neurology·2026

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Fred Kim1, Tianyang Xi1, Han Joo Lee2

  • 1AriBio Co., Ltd., San Diego, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

AR1001 (mirodenafil) muestra promesa como monoterapia para la enfermedad de Alzheimer (EA). En un ensayo de fase 2, 30 mg de AR1001 mejoraron significativamente la cognición y redujeron los biomarcadores de EA en pacientes que no tomaban otros medicamentos para la EA.

Palabras clave:
desarrollo de fármacosAR1001mirodenafilenfermedad de Alzheimerensayo clínicomonoterapiacogniciónbiomarcadoresPDE5tau

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia
  • Farmacología
  • Biomarcadores

Sus antecedentes:

  • AR1001 (mirodenafil) es un inhibidor oral de la fosfodiesterasa 5 (PDE5) en investigación para la enfermedad de Alzheimer (EA).
  • Un ensayo de fase 2 evaluó la seguridad y eficacia de AR1001 en pacientes con EA de leve a moderada.
  • AR1001 demostró seguridad aceptable en dosis de 10 mg y 30 mg durante 26 semanas.

Objetivo del estudio:

  • Evaluar la seguridad y eficacia de AR1001 en pacientes con EA de leve a moderada.
  • Evaluar el impacto de AR1001 en la función cognitiva y los biomarcadores de EA.
  • Explorar el potencial de AR1001 como monoterapia para la EA.

Principales métodos:

  • Un ensayo aleatorizado, doble ciego y controlado con placebo en el que participaron 210 pacientes con EA de leve a moderada.
  • Los participantes recibieron dosis orales diarias de placebo, 10 mg de AR1001 o 30 mg de AR1001 durante 26 semanas.
  • Los análisis de subgrupos examinaron los efectos según el uso de medicación concomitante para la EA, centrándose en el ADAS-Cog-13 y los biomarcadores en plasma (ptau-181, ptau-217).

Principales resultados:

  • Si bien el punto final principal (ADAS-Cog-13) no mostró diferencias significativas en general, el grupo de AR1001 de 30 mg mostró una reducción de ptau-181 y ptau-217 en plasma en comparación con el placebo.
  • En los participantes que no tomaban medicación concomitante para la EA, la monoterapia con AR1001 de 30 mg mostró una mejora estadísticamente significativa en el ADAS-Cog-13 (p=0,012).
  • La monoterapia con AR1001 de 30 mg también condujo a reducciones significativas en ptau-181 (p=0,023) y ptau-217 (p<0,05) en plasma en comparación con el placebo.

Conclusiones:

  • AR1001 (mirodenafil) a 30 mg demostró potencial como monoterapia para la enfermedad de Alzheimer.
  • El análisis de subgrupos indicó que los pacientes tratados con AR1001 de 30 mg sin otros medicamentos para la EA experimentaron beneficios cognitivos.
  • El estudio destaca el potencial de AR1001 para modificar la progresión de la EA mediante la reducción de biomarcadores patológicos clave.